USFDA Warning: Risk of dental problems with Buprenorphine use
New Delhi: The U.S. health regulator on Wednesday warned patients and prescribers about the risk of potential dental problems arising from the use of buprenorphine medicines to treat opioid addiction and pain.
The Food and Drug Administration said the opioid addiction treatment has been reported to cause tooth decay, infection, and, in some cases, total tooth loss in patients with no history of dental issues.
The regulator's approved buprenorphine products include Orexo's Zubsolv, Indivior's Suboclade, among others.
The benefits of buprenorphine medicines for opioid use disorder and pain clearly outweigh the risks, and are important tools in treating these conditions, the FDA said.
Read also: USFDA warns against rare bleeding risk of JnJ COVID vaccine
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.